HALLUCINOGENS: A SPECIAL CLASS OF SUBSTANCES?
- Authors: Sivolap Y.P1
-
Affiliations:
- First Moscow State University
- Issue: Vol XLIX, No 2 (2017)
- Pages: 75-77
- Section: Articles
- URL: https://journal-vniispk.ru/1027-4898/article/view/14076
- DOI: https://doi.org/10.17816/nb14076
- ID: 14076
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Yuri P Sivolap
First Moscow State University
Email: yura-sivolap@yandex.ru
department of psychiatry and narcology 119991, Trubetskaya Str., 8 (2), Moscow
References
- Belgers M., Leenaars M., Homberg J.R. et al. Ibogaine and addiction in the animal model, a systematic review and meta-analysis // Transl Psychiatry. 2016. Vol. 6 (5). P. e826.
- Bogenschutz M.P., Johnson M.W. Classic hallucinogens in the treatment of addictions // Prog Neuropsychopharmacol Biol Psychiatry. 2016. Vol. 64. P. 250-258.
- Gunduz-Bruce H., Kenney J., Changlani S. et al. A translational approach for NMDA receptor profiling as a vulnerability biomarker for depression and schizophrenia // Exp Physiol. 2017. [Epub ahead of print].
- Murrough J.W., Abdallah C.G., Mathew S.J. Targeting glutamate signalling in depression: progress and prospects // Nat Rev Drug Discov. 2017. [Epub ahead of print].
- Ruiz P., Strain E.C. The Substance Use: Handbook. / Second Edition. Philadelphia: Lippincott, Williams & Wilkins, 2014. 558 p.
- Ryan W.C., Marta C.J., Koek R.J. Ketamine, Depression and Current Research: A Review of the Literature. In: The Ketamine Papers: Science, Therapy, and Transformation. Santa Cruz: MAPS, 2016. P. 199-273.
- Zdrojewicz Z., Kuszczak B., Olszak N. Ibogaine - structure, influence on human body, clinical relevance // Pol Merkur Lekarski. 2016. Vol. 41 (241). P. 50-55.
Supplementary files
